Ceryx Medical has announced that the first patient has been enrolled in the RSA-Pace multicentre study at Waikato Hospital in Hamilton, New Zealand evaluating the safety of the Cysoni temporary pacing technology in the treatment of post-surgical heart failure patients that require temporary pacing.
The RSA-Pace study will enrol up to 60 patients at centres in the UK, New Zealand and Australia.
“We are delighted to have enrolled the first patient in this important study. The Ceryx Cysoni pre-clinical results have been most impressive and have shown that this technology has the potential to improve cardiac output compared to existing pacing technologies. This is an exciting and novel approach, and we are interested to understand the benefits of RSA pacing in a post-surgical patient population” said Martin Stiles, principal investigator at Waikato Hospital.
“We would like to thank Dr Stiles and the team at Waikato,” said Stuart Plant CEO, Ceryx. “We believe that the results from this first-in-human study will help us understand the role of RSA pacing as we strive to develop temporary and permanent pacing devices based on this unique technology. We are exceptionally pleased with the performance of the Cysoni system so far, it’s ability to restore RSA appears to be exceeding our expectations.”
